Status: Recruiting
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.
Participants needed: 21
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Enliven TherapeuticsUpdated: Jul 1, 2025Locations: 4
Eligibility criteria
BCR::ABL1 positive CP-CML that has failed, or the patient is intolerant to, or n... [+4]
Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives, wh... [+2]